The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients
Open accessAbstract
Matrix metalloprotease-9 (MMP-9; 92 kDa type IV collaganase, gelatinase B) is regarded as, important for degradation of the basement membrane and extracellular matrix during cancer invasion and other tissue-remodelling events. In this study we evaluate the prognostic value of MMP-9, by immunoperoxidase staining in a series of 210 breast cancer tissues. The results were quantitated using the HSCORE system, which consider both staining intensity and the percentage of cells stained at given intensities. MMP-9 status was compared with the concentration of cytosolic Cathepsin-D and with other established prognostic factors, in terms of disease free survival and overall survival. The median follow-up period was 62 months. MMP-9 staining was observed primarily in cancer cells, and to a lesser degree in surrounding stromal cells. MMP-9 expression was not detected in normal breast tissue. Levels of MMP-9 expression below the cut-off point were more frequently observed in larger (P = 0.014), invasive ductal histologic (P = 0.037), progesterone receptor (PR)-negative and PR-strong positive tumours (P< 0.001), as well as samples belonging to patients with stage III-IV disease (P = 0.009) and age 45-55 years (P = 0.011). In univariate analysis, node-negative breast cancer patients with tumors positive for MMP-9 had a considerable reduction in risk for relapse (RR = 0.45;P = 0.039) or death (RR = 0.32;P = 0.009). Multivariate analysis indicated that MMP-9 status was an independent favourable predictor of OS (RR = 0.47;P = 0.034) in node-negative but not in node-positive patients. Our results suggest that MMP-9 may be an independent favourable prognostic factor in node-negative breast cancer patients. The overexpression of MMP-9 in breast cancer may be also used as a marker to subdivide node negative breast cancer patients in order to determine the optimal treatment modality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase
Strongin, A. Y., Collier, I., Bannikov, G., Marmer, B. L., Grant, G. A., & Goldberg, G. I. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.10.5331 · Cited by 1,593
Changing views of the role of matrix metalloproteinases in metastasis
Chambers, A. F., & Matrisian, L. M. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.17.1260 · Cited by 1,588
Jonat, C., Rahmsdorf, H. J., Park, K.-K., Cato, A. C. B., Gebel, S., Ponta, H., & Herrlich, P. (1990) · Cell · doi:10.1016/0092-8674(90)90395-u · Cited by 1,566
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
Nelson, A. R., Fingleton, B., Rothenberg, M. L., & Matrisian, L. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1135 · Cited by 1,554
Mammalian Membrane-bound Adenylyl Cyclases
Taussig, R., & Gilman, A. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.1.1 · Cited by 721
Yu, Q., & Stamenkovic, I. (1999) · Genes & Development · doi:10.1101/gad.13.1.35 · Cited by 713
Tumor invasion and metastasis: an imbalance of positive and negative regulation.
Liotta, L. A., & Stetler‐Stevenson, W. G. (1991) · PubMed · Cited by 705
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
Bajou, K., Noël, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0898-923 · Cited by 677
Goss, K. H., Matrisian, L. M., Jensen, R. A., & Rodgers, W. H. (1996) · Europe PMC (PubMed Central) · Cited by 504
Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2).
Fridman, R., Tóth, M., Peña, D., & Mobashery, S. (1995) · PubMed · Cited by 378
Le Doussal, V., Tubiana-Hulin, M., Friedman, S., Hacene, K., Spyratos, F., & Brunet, M. (1989) · Cancer · doi:10.1002/1097-0142(19891101)64:9<1914::aid-cncr2820640926>3.0.co;2-g · Cited by 377
Type IV collagenases in invasive tumors
Tryggvason, K., Höyhtyä, M., & Pyke, C. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf01833261 · Cited by 249
ZUCKER, S., HYMOWITZ, M., CONNER, C., ZARRABI, H. M., HUREWITZ, A. N., MATRISIAN, L., BOYD, D., NICOLSON, G., & MONTANA, S. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07687.x · Cited by 236
The Urokinase Receptor. Protein Structure and Role in Plasminogen Activation and Cancer Invasion
DANØ, K., BEHRENDT, N., BRUNNER, B., ELLIS, V., PLOUG, M., & PYKE (1995) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.6.212 · Cited by 234
Bruner, K. L., Rodgers, W. H., Gold, L. I., Korc, M., Hargrove, J. T., Matrisian, L. M., & Osteen, K. G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7362 · Cited by 222
Jones, J. L., Glynn, P., & Walker, R. A. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199910)189:2<161::aid-path406>3.0.co;2-2 · Cited by 183
Cathepsin B and human tumor progression.
Yan, S., Sameni, M., & Sloane, B. F. (1998) · PubMed · Cited by 173
Nielsen, B. S., Timshel, S., Kjeldsen, L., Sehested, M., Pyke, C., Borregaard, N., & Danø, K. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960103)65:1<57::aid-ijc10>3.0.co;2-f · Cited by 173
Gelatinase B: Structure, Regulation, and Function
Vu, T. H., & Werb, Z. (1998) · Matrix Metalloproteinases · doi:10.1016/b978-012545090-4/50006-9 · Cited by 168
Visscher, D. W., Höyhtyä, M., Ottosen, S. K., Liang, C., Sarkar, F. H., Crissman, J. D., & Fridman, R. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590308 · Cited by 162
Sugiura, Y., Shimada, H., Seeger, R. C., Laug, W. E., & DeClerck, Y. A. (1998) · PubMed · Cited by 154
Salamonsen, L. A., Butt, A. R., Hammond, F. R., Garcia, S., & Zhang, J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.5.3920 · Cited by 140
Molecular Cloning of the Human Kallikrein 15 Gene (KLK15)
Yousef, G. M., Scorilas, A., Jung, K., Ashworth, L. K., & Diamandis, E. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005432200 · Cited by 120
Self-citationNielsen, B. S., Sehested, M., Timshel, S., Pyke, C., & Danø, K. (1996) · PubMed · Cited by 114
Mira, E., Mañes, S., Lacalle, R. A., Márquez, G., & Martínez‐A, C. (1999) · Endocrinology · doi:10.1210/endo.140.4.6623 · Cited by 100
Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer.
Nielsen, B. S., Sehested, M., Kjeldsen, L., Borregaard, N., Rygaard, J., & Danø, K. (1997) · PubMed · Cited by 93
Pacheco, M. M., Mourao, M., Mantovani, E. B., Nishimoto, I. N., & Brentani, M. M. (1998) · Clinical & Experimental Metastasis · doi:10.1023/a:1006580415796 · Cited by 88
Proteolysis in human breast and colorectal cancer
Garbett, E. A., Reed, M., & Brown, N. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690689 · Cited by 87
Stromal Cell Expression of Components of Matrix-Degrading Protease Systems in Human Cancer
Hewitt, R. E., & Danø, K. (2017) · Enzyme and Protein · doi:10.1159/000468623 · Cited by 82
Scorilas, A., Black, M. H., Talieri, M., & Diamandis, E. P. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3807 · Cited by 81
Self-citationTakeha, S., Fujiyama, Y., Bamba, T., Sorsa, T. A., Nagura, H., & Ohtani, H. (1997) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1997.tb00304.x · Cited by 76
Yousef, G. M., Scorilas, A., & Diamandis, E. P. (2000) · Genomics · doi:10.1006/geno.1999.6072 · Cited by 71
Self-citationBlavier, L., & DeClerck, Y. A. (1997) · Molecular Biology of the Cell · doi:10.1091/mbc.8.8.1513 · Cited by 56
Pepsinogen C is a new prognostic marker in primary breast cancer.
Vizoso, F. J., Sánchez, L., Diez‐Itza, I., Merino, A. M., & López-Otín, C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.54 · Cited by 47
El-Ashry-Stowers, D., Zava, D. T., Speers, W. C., et al. (1988) · PubMed · Cited by 44
Scorilas, A., Talieri, M., Ardavanis, A. S., Courtis, N., Dimitriadis, E., Yotis, J., Tsiapalis, C. M., & Trangas, T. T. (2000) · PubMed · Cited by 33
Self-citation
Cited by
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Emerging roles of proteases in tumour suppression
López-Otín, C., & Matrisian, L. M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2228 · Cited by 802
Gelatinase-mediated migration and invasion of cancer cells
Björklund, M., & Koivunen, E. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.03.001 · Cited by 661
Chung, T., Moon, S., Chang, Y., Ko, J., Lee, Y., Cho, G., Kim, S., Kim, J., & Kim, C. (2004) · The FASEB Journal · doi:10.1096/fj.04-2126com · Cited by 456
Mehner, C., Hockla, A., Miller, E., Ran, S., Radisky, D. C., & Radisky, E. S. (2014) · Oncotarget · doi:10.18632/oncotarget.1932 · Cited by 368
Metadata
- Authors
- Scorilas, A., Karameris, A., Arnogiannaki, N., Ardavanis, A., Bassilopoulos, P., Trangas, T., & Talieri, M.
- Venue
- British Journal of Cancer
- Published
- 2001
- Volume
- 84
- Issue
- 11
- Pages
- 1488-1496
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2022518765
- Cited by
- 258
- References
- 38
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.